Compare SGRP & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRP | GLTO |
|---|---|---|
| Founded | 1967 | 2011 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3M | 23.7M |
| IPO Year | 1996 | 2020 |
| Metric | SGRP | GLTO |
|---|---|---|
| Price | $0.86 | $29.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 67.6K | ★ 519.8K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $147,130,000.00 | N/A |
| Revenue This Year | $7.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.79 | N/A |
| 52 Week Low | $0.85 | $2.01 |
| 52 Week High | $2.10 | $33.60 |
| Indicator | SGRP | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 32.37 | 70.58 |
| Support Level | $0.85 | $16.70 |
| Resistance Level | $0.92 | $29.03 |
| Average True Range (ATR) | 0.05 | 2.60 |
| MACD | -0.00 | 0.64 |
| Stochastic Oscillator | 6.67 | 94.66 |
SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. It also provides a range of services to retailers, consumer goods manufacturers and distributors around the globe. The company divides its operations into three reportable regional segments: Americas, which is comprised of United States, Canada, Brazil and Mexico; Asia-Pacific (APAC), which is comprised of Japan, China, and India; and Europe, Middle East and Africa (EMEA), which is comprised of South Africa. It generates maximum revenue from the Americas.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.